Our finding of significantly reduced paraxanthine at baseline in PD-LRRK2 and PD-GBA1 cohorts therefore aligns with these metabolomic signatures and suggests that diminished paraxanthine exposure—or accelerated clearance—may associate with elevated risk or earlier phenoconversion in these genotypes. This evidence concerns the gene LRRK2 and Parkinson disease.